Breaking News Instant updates and real-time market news.

ALGN

Align Technology

$212.54

5.75 (2.78%)

, ABC

AmerisourceBergen

$76.04

-1.32 (-1.71%)

09:25
01/18/19
01/18
09:25
01/18/19
09:25

UBS healthcare supply chain analysts to hold analyst/industry conference call

Analysts discuss the initiation of coverage for ALGN, ABC, CVS, LH, PNIC (Buys), HSIC, WBA (Sells) and CAH, XRAY, MCK, OMI, PDCO, DGX (Neutrals) on an Analyst/Industry conference call to be held on January 18 at 10 am.

ALGN

Align Technology

$212.54

5.75 (2.78%)

ABC

AmerisourceBergen

$76.04

-1.32 (-1.71%)

CVS

CVS Health

$63.36

-0.54 (-0.85%)

LH

LabCorp

$135.25

3.25 (2.46%)

HSIC

Henry Schein

$78.28

-1.72 (-2.15%)

WBA

Walgreens Boots Alliance

$71.94

-0.05 (-0.07%)

CAH

Cardinal Health

$48.17

-0.26 (-0.54%)

XRAY

Dentsply Sirona

$40.24

0.1 (0.25%)

MCK

McKesson

$124.39

0.74 (0.60%)

OMI

Owens & Minor

$7.31

-0.32 (-4.19%)

PDCO

Patterson Companies

$22.15

-0.07 (-0.32%)

DGX

Quest Diagnostics

$85.12

0.89 (1.06%)

  • 18

    Jan

  • 21

    Jan

  • 29

    Jan

  • 31

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 14

    Feb

ALGN Align Technology
$212.54

5.75 (2.78%)

01/04/19
MSCO
01/04/19
NO CHANGE
Target $210
MSCO
Equal Weight
Morgan Stanley says dental survey negative for Align, positive for Straumann
Morgan Stanley analyst Steve Beuchaw noted that the firm surveyed 30 dentists and 42 orthodontists in the U.S. and said the results points to slower aligner mix shift and emerging share movements, both of which he said are negative for Align Technology (ALGN). He further points out that the survey was run during 4Q, in advance of the full launch of competing products from 3M (MMM), Danaher (DHR) and Dentsply Sirona (XRAY). Given the survey findings, Beuchaw cut his U.S. volume estimates for Align by 400bps for 2019 and lowered his price target on the stock to $210 from $300 to account for lower estimates and a lower market multiple. He maintains an Equal Weight rating on Align Technology shares. Beuchaw added that the survey was positive for Straumann (STMN), which is covered by Michael Jungling. While investors tend to focus on new entrants from the other three mentioned above, ClearCorrect with support from Straumann was the bigger share winner prospectively in the survey, Beuchaw tells investors.
01/02/19
BARD
01/02/19
NO CHANGE
Target $255
BARD
Outperform
Align Technology price target lowered to $255 from $330 at Baird
Baird analyst Jeff Johnson lowered his price target on Align Technology to $255 from $330 as he turned more cautious on the space due to the combination of the dental sector's secular overhangs, softer Q4 patient volume checks, and accelerating equipment pricing pressures. Johnson maintained his Outperform rating on Align Technology shares, citing its big addressable market, reasonable valuation, and solid Invisalign December survey data.
12/27/18
GSCO
12/27/18
NO CHANGE
GSCO
Goldman sees potential for softer macro to weigh on U.K. dental, vet spending
Goldman Sachs analyst Nathan Rich said several recent data points, including consumer spending data and Walgreens Boots Alliance's (WBA) results, suggest a more challenging environment for U.K. consumers. Given this, he sees potential for the softer U.K. macro backdrop to weigh on spending for dental and vet services. Rich noted that Patterson (PDCO) generates the highest percentage of revenue in the U.K. among dental names he covers, at 11%, adding that Align Technology (ALGN), Henry Schein (HSIC) and Dentsply Sirona (XRAY) each have about 5% exposure on average.
01/17/19
UBSW
01/17/19
INITIATION
Target $230
UBSW
Buy
Align Technology initiated with a Buy at UBS
UBS analyst Kevin Caliendo started Align Technology with a Buy rating and $230 price target. The analyst thinks near-term fears around broad dental demand, average selling prices and competition in the aligner space are overshadowing the big picture in Align. The company has dominant market share and best-in-class technology in an underpenetrated market, says the analyst. He believes the company's 2019 outlook call will be a "clearing event" for the shares.
ABC AmerisourceBergen
$76.04

-1.32 (-1.71%)

01/17/19
UBSW
01/17/19
INITIATION
Target $89
UBSW
Buy
AmerisourceBergen initiated with a Buy at UBS
UBS analyst Kevin Caliendo started AmerisourceBergen with a Buy rating and $89 price target. The fundamentals that have historically driven AmerisourceBergen's stock have all improved in recent months, Caliendo tells investors in a research note. He believes near-term visibility offsets the company's opioid and long-term pressures.
07/20/18
07/20/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Philip Morris (PM) downgraded to Neutral from Overweight at JPMorgan and to Market Perform from Outperform at Cowen. 2. Skechers (SKX) downgraded to Neutral from Positive at Susquehanna and to Market Perform from Outperform at Wells Fargo. 3. McKesson (MCK), AmerisourceBergen (ABC), and Express Scripts (ESRX) downgraded to Neutral from Outperform at Baird. 4. Five Below (FIVE) downgraded to Neutral from Outperform at Credit Suisse with analyst Judah Frommer saying he is moving to the sidelines as he sees risk/reward balanced at current levels given the stock's material outperformance and back-half comp acceleration that he believes is priced into shares. 5. Yum China (YUMC) downgraded to Underperform from Neutral at BofA/Merrill with analyst Chen Luo saying he expects Yum China to continue to underperform given a likely peak in KFC trends amid China's weakening macro environment, a likely prolonged turnaround at Pizza Hut combined with heavy costs, a slowdown in Chinese consumer consumption, and RMB depreciation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/20/18
BARD
07/20/18
DOWNGRADE
BARD
Neutral
Express Scripts, AmerisourceBergen, McKesson cut to Neutral at Baird
As previously reported, Baird analyst Eric Coldwell downgraded Express Scripts (ESRX), AmerisourceBergen (ABC) and McKesson (MCK), all to Neutral from Outperform, citing the heavy political attack in recent weeks against PBMs and members of the drug supply chain. Among them, he said AmerisourceBergen remains his preferred name, but he cannot justify putting new money to work in these names in the current environment, stating that visibility has deteriorated further across the supply chain.
07/20/18
07/20/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BOFA CUTS YUM CHINA TO UNDERPERFORM: BofA Merrill Lynch analyst Chen Luo downgraded Yum China (YUMC) to Underperform from Neutral and cut its price target to $34 from $44.30. Luo said he expects Yum China to continue to underperform given a likely peak in KFC trends amid China's weakening macro environment, a likely prolonged turnaround at Pizza Hut combined with heavy costs, a slowdown in Chinese consumer consumption, and RMB depreciation. Yum China is down 4.8% in late morning trading. CREDIT SUISSE CUTS FIVE BELOW TO NEUTRAL: Credit Suisse analyst Judah Frommer downgraded Five Below (FIVE) to Neutral from Outperform, telling investors that he is moving to the sidelines as he sees risk/reward balanced at current levels given the stock's material outperformance and back-half comp acceleration that he believes is priced into shares. Frommer keeps his $110 price target and says Five Below remains one of the most differentiated concepts in retail. Five Below is down 4.4% in late morning trading. BAIRD MORE CAUTIOUS ON DRUG SUPPLY CHAIN: Baird analyst Eric Coldwell downgraded Express Scripts (ESRX), AmerisourceBergen (ABC), and McKesson (MCK), all to Neutral from Outperform, citing the heavy political attack in recent weeks against pharmacy benefit managers and members of the drug supply chain. Among them, he said AmerisourceBergen remains his preferred name, but he cannot justify putting new money to work in these names in the current environment. SUNTRUST STARTS VIKING WITH A BUY: SunTrust analyst Edward Nash initiated Viking Therapeutics (VKTX) with a Buy rating and a price target of $14, saying its VK2809 drug for lipid disorders "has the potential to become a promising treatment by addressing multiple metabolic issues" associated with the non-alcoholic steatohepatitis disease, or NASH. Viking is up 8.3% in late morning trading. JPMORGAN SAYS BUY GM, SELL TESLA INTO EARNINGS: JPMorgan analyst Ryan Brinkman forecast lower than consensus Q2 earnings for Ford (F) and higher than consensus earnings for General Motors (GM). The analyst is also concerned about the potential for a "large loss and accompanying large cash outflow" at Tesla (TSLA) in Q2 to "make the bridge" to GAAP profitability and positive cash generation in the second half of the year. Brinkman maintained Overweight ratings on GM and Ford, with a preference for GM shares. He also kept his cautious Underweight rating on Tesla shares, seeing 44% downside to his $180 December 2018 price target.
CVS CVS Health
$63.36

-0.54 (-0.85%)

01/17/19
01/17/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tencent Music (TME) initiated with an Overweight at JPMorgan. 2. Craft Brew (BREW) initiated with a Buy at Maxim while Castle Brands (ROX) was initiated with a Hold. 3. CVS Health (CVS) and LabCorp (LH) were initiated with a Buy at UBS while Walgreens Boots Alliance (WBA) was initiated with a Sell. 4. DTE Energy (DTE) initiated with a Buy at Goldman Sachs while CMS Energy (CMS) was initiated with a Neutral. 5. Zendesk (ZEN) and HubSpot (HUBS) were initiated with an Overweight at Stephens while Adobe (ADBE) was initiated with an Equal Weight. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/17/19
UBSW
01/17/19
INITIATION
Target $75
UBSW
Buy
CVS Health initiated with a Buy at UBS
UBS analyst Kevin Caliendo started CVS Health with a Buy rating and $75 price target. Concerns around 2019 earnings guidance and the timing of the next positive catalyst have pushed CVS stock down to a "very appealing" risk/reward profile, Caliendo tells investors in a research stone.
01/16/19
MSCO
01/16/19
NO CHANGE
MSCO
Morgan Stanley says UnitedHealth, Walgreens could benefit from CVS-Walmart fight
After CVS Health (CVS) announced Walmart (WMT) will leave Caremark's commercial and Managed Medicaid retail pharmacy networks at the end of April 2019, analysts at Morgan Stanley discussed the potential impact of the fight to both companies and to competitors. Analyst Ricky Goldwasser said the dispute "brings back memories" of the Express Scripts (ESRX) and Walgreens (WBA) breakup in 2011, but unlike in that case it is only the early days of the 2019/2020 selling season, not after the selling season concluded. Walmart's plans to leave should have a limited impact on CVS' FY19 EPS power, but adds uncertainty to PBM selling season if not resolved in the near-term, said Goldwasser. Morgan Stanley's Simeon Gutman said that if the dispute is not resolved, it could end up reducing Walmart's EBIT by about $260M in 2019, which he estimates could have a 7c, or 1.5%, impact on EPS. In terms of who may benefit if no resolution is reached, the team estimates both Walgreens and CVS retail could gain an incremental 25 bps of pharmacy share and that UnitedHealth's (UNH) Optum and Cigna (CI) could see a step up in PBM selling season win rates. However, given Walmart's relatively low share, they view the PBM share opportunity as "minimal."
01/14/19
COWN
01/14/19
NO CHANGE
Target $103
COWN
Outperform
CVS Health headwind concerns overblown, says Cowen
Cowen analyst Charles Ryhee updated his model on CVS (CVS) to reflect headwinds from rebate guarantees and Aetna's (AET) large group rated business. He believes the pressure on the shares due to rebate guarantees is overdone in that it represents less than 2% of its revenues. Ryhee reiterated his Outperform rating and $103 price target on CVS shares.
LH LabCorp
$135.25

3.25 (2.46%)

01/03/19
BOFA
01/03/19
DOWNGRADE
BOFA
Underperform
LabCorp downgraded to Underperform from Neutral at BofA/Merrill
01/03/19
01/03/19
DOWNGRADE

Underperform
LabCorp downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill downgraded LabCorp to Underperform from Neutral and lowered its price target to $120 from $152. Analyst Derik de Bruin said LabCorp is operating in a price deflationary environment due to headwinds from the Protecting Access to Medicare Act and contract openings for lab contracts. de Bruin views the current environment for labs as unlike prior periods and said recent soft volume trends may be a prelude to deeper structural issues not fully understood by the market
01/17/19
UBSW
01/17/19
INITIATION
Target $169
UBSW
Buy
LabCorp initiated with a Buy at UBS
UBS analyst Kevin Caliendo started LabCorp with a Buy rating and $169 price target. The analyst thinks Diagnostic EBIT stabilization in the second half of 2019 should provide "support to a re-rating" of the company's multiple. Caliendo sees 2%-7% upside to consensus earnings estimates over the long term driven by high-single-digit Covance revenue growth and capital allocation. The recent underperformance of LabCorp creates a positive risk/reward setup into the 2019 guidance call, says the analyst.
HSIC Henry Schein
$78.28

-1.72 (-2.15%)

01/17/19
UBSW
01/17/19
INITIATION
Target $73
UBSW
Sell
Henry Schein initiated with a Sell at UBS
UBS analyst Kevin Caliendo started Henry Schein with a Sell rating and $73 price target. The analyst's long-term EBIT and earnings estimates are below consensus as he expects ongoing margin pressures to offset Henry Schein's cost saving initiatives and partnership synergies.
01/03/19
EVER
01/03/19
DOWNGRADE
EVER
Underperform
Henry Schein downgraded to Underperform at Evercore ISI
As previously reported, Evercore ISI downgraded Henry Schein to Underperform from In Line. Analyst Ross Muken remains negative on the Dental complex given long-term risks to margins due to pricing, competition, and disintermediation. Muken expects a moderation in the company's share gains in consumables/high-tech equipment, and said the CVET spin is near completion with underling profit likely lower short-term.
01/03/19
EVER
01/03/19
DOWNGRADE
EVER
Underperform
Henry Schein downgraded to Underperform from In Line at Evercore ISI
01/02/19
01/02/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Henry Schein (HSIC) downgraded to Neutral from Outperform at Baird with analyst Jeff Johnson saying he is more cautious on the combination of the dental sector's secular overhangs, softer Q4 patient volume checks, and accelerating equipment pricing pressures. 2. Conagra Brands (CAG) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Jason English saying while the stock's 41% decline since October 23 is overdone, the "path of recovery is likely to be protracted." 3. BioMarin (BMRN) downgraded to Market Perform from Outperform at Raymond James with analyst Laura Chico saying BioMarin lacks near-term catalysts which makes it more vulnerable in a "risk off" environment. 4. Hologic (HOLX) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst David Lewis saying his checks with about 40 medspas highlighted market saturation of body sculpting devices. 5. Louisiana-Pacific (LPX) downgraded to Neutral from Buy at BofA/Merrill with analyst George Staphos citing the steep drop-off in 2H 2018 panel pricing and challenging 1H 2019 comparisons versus 1H 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
WBA Walgreens Boots Alliance
$71.94

-0.05 (-0.07%)

01/17/19
UBSW
01/17/19
INITIATION
Target $70
UBSW
Sell
Walgreens Boots Alliance initiated with a Sell at UBS
UBS analyst Kevin Caliendo started Walgreens Boots Alliance with a Sell rating and $70 price target. The analyst's work suggests the company's core retail margins will stay pressured over the next several years. Further, he believes Walgreens' industry dynamics remain challenging.
CAH Cardinal Health
$48.17

-0.26 (-0.54%)

11/16/18
11/16/18
DOWNGRADE
Target $55

Market Perform
Cardinal Health downgraded to Market Perform from Outperform at Leerink
Leerink analyst David Larsen downgraded Cardinal Health to Market Perform from Outperform and lowered his price target to $55 from $60. In a research note to investors, Larsen says that a recent MEDACorp survey shows that the level of distributor RFP activity may be increasing, which could lead to more pricing pressure, and that survey data shows that a significant portion of Cardinal clients do not view Cardinal as being the most competitively priced. In addition, Larsen believes that Cardinal is heavily dependent on January price increases which may disappoint, the company's Medical Division continues to face major persistent challenges from Cordis, and the core Medical business itself also seems to have slowed.
01/17/19
UBSW
01/17/19
INITIATION
Target $51
UBSW
Neutral
Cardinal Health initiated with a Neutral at UBS
UBS analyst Kevin Caliendo started Cardinal Health with a Neutral rating and $51 price target.
09/21/18
RBCM
09/21/18
NO CHANGE
Target $60
RBCM
Sector Perform
Cardinal Health price target raised to $60 from $56 at RBC Capital
RBC Capital analyst George Hill raised his price target on Cardinal Health to $60 on slight adjustment of his rolled-forward model related to the timing of the company's earnings. The analyst keeps his Sector Perform rating however and warns that operational issues in its Medical business will weight on the results while its brand drug business also proves to be "optimistic". Hill further contends that Cardinal Health's brand drug pricing increase may come in below expectations, lowering FY19 EPS view to $4.79 from $4.87 which is below its current guidance range of $4.90-$5.15.
11/16/18
LEER
11/16/18
DOWNGRADE
LEER
Market Perform
Cardinal Health downgraded to Market Perform from Outperform at Leerink
XRAY Dentsply Sirona
$40.24

0.1 (0.25%)

01/17/19
UBSW
01/17/19
INITIATION
Target $43
UBSW
Neutral
Dentsply Sirona initiated with a Neutral at UBS
UBS analyst Kevin Caliendo started Dentsply Sirona with a Neutral rating and $43 price target.
10/19/18
10/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Overweight from Equal Weight at Barclays with analyst Kannan Venkateshwar saying the stock is likely to become a "core holding" again. 2. Dentsply Sirona (XRAY) double upgraded to Buy from Sell at Goldman Sachs with analyst Nathan Rich saying he now believes consensus estimates are achievable and that Dentsply's valuation is attractive relative to Medtech peers. 3. PayPal (PYPL) upgraded to Buy from Neutral at BTIG with analyst Mark Palmer saying the company's Venmo monetization progress was the deciding factor in his rating change. 4. Roku (ROKU) upgraded to Outperform from Sector Perform at RBC Capital with analyst Mark Mahaney saying the company's valuation has become more attractive following a 25% pullback in its stock price but believes Roku offers the "best opportunity for upwards estimates revisions." 5. O'Reilly Automotive (ORLY) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Horvers saying he sees "strong" fundamentals with "structurally positive industry factors." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MCK McKesson
$124.39

0.74 (0.60%)

01/17/19
UBSW
01/17/19
INITIATION
Target $134
UBSW
Neutral
McKesson initiated with a Neutral at UBS
UBS analyst Kevin Caliendo started McKesson with a Neutral rating and $134 price target.
OMI Owens & Minor
$7.31

-0.32 (-4.19%)

01/17/19
UBSW
01/17/19
INITIATION
Target $8
UBSW
Neutral
Owens & Minor initiated with a Neutral at UBS
UBS analyst Kevin Caliendo started Owens & Minor with a Neutral rating and $8 price target.
10/31/18
BOFA
10/31/18
DOWNGRADE
BOFA
Neutral
Owens & Minor downgraded to Neutral from Buy at BofA/Merrill
03/08/18
LEHM
03/08/18
INITIATION
Target $16
LEHM
Underweight
Owens & Minor initiated with an Underweight at Barclays
Barclays analyst Steve Valiquette started Owens & Minor with an Underweight rating and $16 price target. The analyst initiated 14 companies in Health Care Services with a Neutral industry view.
02/27/18
BOFA
02/27/18
INITIATION
Target $19
BOFA
Buy
Owens & Minor reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on Owens & Minor with a Buy and $19 price target.
PDCO Patterson Companies
$22.15

-0.07 (-0.32%)

01/03/19
EVER
01/03/19
UPGRADE
EVER
In Line
Patterson Companies upgraded to In Line from Underperform at Evercore ISI
01/03/19
EVER
01/03/19
UPGRADE
EVER
In Line
Patterson Companies upgraded to In Line at Evercore ISI
As previously reported, Evercore ISI upgraded Patterson Companies to In Line from Underperform. Analyst Ross Muken said recent management actions to remove credit and dividend risk have enhanced financial flexibility, and the restructuring and sales force additions likely support earnings at current levels.
01/17/19
UBSW
01/17/19
INITIATION
Target $23
UBSW
Neutral
Patterson Companies initiated with a Neutral at UBS
UBS analyst Kevin Caliendo started Patterson Companies with a Neutral rating and $23 price target.
DGX Quest Diagnostics
$85.12

0.89 (1.06%)

01/03/19
BOFA
01/03/19
DOWNGRADE
BOFA
Underperform
Quest Diagnostics downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill downgraded Quest Diagnostics to Underperform from Neutral and lowered its price target to $72 from $93. Analyst Derik de Bruin said Quest is operating in a price deflationary environment due to headwinds from the Protecting Access to Medicare Act and contract openings for lab contracts. de Bruin views the current environment for labs as unlike prior periods and said recent soft volume trends may be a prelude to deeper structural issues not fully understood by the market
01/03/19
BOFA
01/03/19
DOWNGRADE
BOFA
Underperform
Quest Diagnostics downgraded to Underperform from Neutral at BofA/Merrill
01/17/19
UBSW
01/17/19
INITIATION
Target $90
UBSW
Neutral
Quest Diagnostics initiated with a Neutral at UBS
UBS analyst Kevin Caliendo started Quest Diagnostics with a Neutral rating and $90 price target.
12/03/18
12/03/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Verizon (VZ) downgraded to Neutral from Overweight at JPMorgan with analyst Philip Cusick saying that as much as he likes Verizon's "consistent and improving execution," the combination of a new management team and reporting lines with the stock's 17% year-to-date increase make the risk/reward less compelling than peers AT&T (T) and Comcast (CMCSA). 2. Costco (COST) downgraded to Neutral from Buy at Citi with analyst Kate McShane saying she sees "more headwinds than tailwinds likely in 2019" for Costco. 3. Tractor Supply (TSCO) downgraded to Perform from Outperform at Oppenheimer with analyst Brian Nagel saying he views lower oil prices as a risk for the company. 4. LabCorp (LH) downgraded to Hold from Buy at Craig-Hallum and to Neutral from Buy at BofA/Merrill. 5. Quest Diagnostics (DGX) downgraded to Neutral from Buy at BofA/Merrill with analyst Derik de Bruin citing the cut in FY18 guidance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

BHGE

Baker Hughes

$26.29

0.01 (0.04%)

13:03
02/22/19
02/22
13:03
02/22/19
13:03
Hot Stocks
Baker Hughes reports U.S. rig count down 4 to 1,047 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 22

    May

  • 28

    May

EFX

Equifax

$110.23

-0.28 (-0.25%)

13:00
02/22/19
02/22
13:00
02/22/19
13:00
Hot Stocks
Equifax says U.S. regulators seek damages related to 2017 breach »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

BILI

Bilibili

$19.48

1.34 (7.39%)

13:00
02/22/19
02/22
13:00
02/22/19
13:00
Options
Bullish option flow in Bilibili as shares rally 7% ahead of earnings »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

VALE

Vale

$12.45

0.43 (3.58%)

12:57
02/22/19
02/22
12:57
02/22/19
12:57
Periodicals
Federal prosecutors in Brazil seek arrest of senior Vale exec, Reuters reports »

Federal prosecutors in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$34.99

-13.2 (-27.39%)

, K

Kellogg

$56.53

-1.8 (-3.09%)

12:57
02/22/19
02/22
12:57
02/22/19
12:57
Periodicals
Prescience Point sees Kellogg following Kraft Heinz with dividend cut »

Short seller Prescience…

KHC

Kraft Heinz

$34.99

-13.2 (-27.39%)

K

Kellogg

$56.53

-1.8 (-3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 03

    Mar

SNAP

Snap

$9.74

0.35 (3.73%)

12:50
02/22/19
02/22
12:50
02/22/19
12:50
Options
Snap calls active as shares see strength »

Snap calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

UBNK

United Financial

$16.11

0.02 (0.12%)

12:49
02/22/19
02/22
12:49
02/22/19
12:49
Hot Stocks
FJ Capital reports 6.47% passive stake in United Financial »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$7.49

-1.47 (-16.41%)

12:48
02/22/19
02/22
12:48
02/22/19
12:48
Hot Stocks
Karyopharm drops 40% after FDA posts Selinexor meeting briefing docs »

Shares of Karyopharm are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

HK

Halcon Resources

$1.67

-0.12 (-6.70%)

12:47
02/22/19
02/22
12:47
02/22/19
12:47
Hot Stocks
Fir Tree comments on Halcon CEO departure, renews call for sale of company »

Fir Tree Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
02/22/19
02/22
12:45
02/22/19
12:45
General news
Breaking General news story  »

Week of 2/22 Baker-Hughes…

KPTI

Karyopharm

$8.97

0.01 (0.11%)

12:43
02/22/19
02/22
12:43
02/22/19
12:43
Hot Stocks
Breaking Hot Stocks news story on Karyopharm »

Karyopharm trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

CMCSA

Comcast

$38.53

0.065 (0.17%)

, CMCSK

Comcast

$0.00

(0.00%)

12:43
02/22/19
02/22
12:43
02/22/19
12:43
On The Fly
Box Office Battle: 'How to Train Your Dragon' sequel flies into theaters »

Welcome to "Box Office…

CMCSA

Comcast

$38.53

0.065 (0.17%)

CMCSK

Comcast

$0.00

(0.00%)

FOX

21st Century Fox

$50.68

0.22 (0.44%)

FOXA

21st Century Fox

$50.97

0.23 (0.45%)

T

AT&T

$31.02

0.19 (0.62%)

DIS

Disney

$115.18

0.88 (0.77%)

LGF.A

Lionsgate

$15.49

0.15 (0.98%)

LGF.B

Lionsgate

$14.65

0.16 (1.10%)

SNE

Sony

$48.02

0.37 (0.78%)

VIA

Viacom

$34.75

(0.00%)

VIAB

Viacom

$29.44

0.25 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 27

    Feb

  • 03

    Mar

  • 04

    Mar

  • 04

    Mar

  • 07

    Mar

  • 11

    Mar

  • 11

    Mar

  • 11

    Mar

  • 20

    Mar

  • 06

    Jun

KPTI

Karyopharm

$9.03

0.07 (0.78%)

12:42
02/22/19
02/22
12:42
02/22/19
12:42
Hot Stocks
Breaking Hot Stocks news story on Karyopharm »

Karyopharm trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

KPTI

Karyopharm

$9.03

0.07 (0.78%)

12:39
02/22/19
02/22
12:39
02/22/19
12:39
Hot Stocks
Breaking Hot Stocks news story on Karyopharm »

Karyopharm drops 16.5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

ATVI

Activision Blizzard

$41.62

-0.28 (-0.67%)

, TTWO

Take-Two

$86.50

-1.08 (-1.23%)

12:37
02/22/19
02/22
12:37
02/22/19
12:37
Periodicals
FTC plans public workshop to go over loot boxes in video games, Verge reports »

The Federal Trade…

ATVI

Activision Blizzard

$41.62

-0.28 (-0.67%)

TTWO

Take-Two

$86.50

-1.08 (-1.23%)

EA

Electronic Arts

$94.44

-2.39 (-2.47%)

UBSFY

Ubisoft

$0.00

(0.00%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 12

    Mar

  • 13

    Mar

  • 21

    Mar

KPTI

Karyopharm

$9.03

0.07 (0.78%)

12:35
02/22/19
02/22
12:35
02/22/19
12:35
Hot Stocks
Karyopharm quickly drops 16.5% »

Shares of Karyopharm have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

KPTI

Karyopharm

$9.04

0.08 (0.89%)

12:32
02/22/19
02/22
12:32
02/22/19
12:32
Hot Stocks
Breaking Hot Stocks news story on Karyopharm »

Karyopharm trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

BIDU

Baidu

$166.90

-4.82 (-2.81%)

12:30
02/22/19
02/22
12:30
02/22/19
12:30
Options
10.1K Baidu Mar 170 - Sep 165 put spreads trade $7.20 after earnings »

10.1K Baidu Mar 170 - Sep…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

UBS

UBS

$12.38

0.055 (0.45%)

12:30
02/22/19
02/22
12:30
02/22/19
12:30
Periodicals
UBS ignored warnings in French tax case for years, Reuters says »

According to a written…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:30
02/22/19
02/22
12:30
02/22/19
12:30
General news
FX Action: USD-JPY »

FX Action: USD-JPY traded…

12:25
02/22/19
02/22
12:25
02/22/19
12:25
General news
Fed VC Clarida said the Fed should be "open minded" »

Fed VC Clarida said the…

GM

General Motors

$39.67

0.04 (0.10%)

12:23
02/22/19
02/22
12:23
02/22/19
12:23
Hot Stocks
GM says over 1,500 employees volunteered to transfer to other U.S. locations »

General Motors said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

GM

General Motors

$39.66

0.03 (0.08%)

12:21
02/22/19
02/22
12:21
02/22/19
12:21
Hot Stocks
GM extends production at Detroit/Hamtramck into January 2020 »

GM said it has notified…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

NWSA

News Corp.

$13.04

0.25 (1.95%)

12:20
02/22/19
02/22
12:20
02/22/19
12:20
Options
Notable print in News Corp puts »

Notable print in News…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
02/22/19
02/22
12:17
02/22/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.